Acurx Pharmaceuticals (ACXP) jumps 68.4% as company outlines recurrent C. diff trial expansion

Acurx Pharmaceuticals, Inc. (ACXP) is up 68.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a newly announced clinical development push to expand ibezapolstat into recurrent C. difficile infection (rCDI), which investors may view as a meaningful program broadening and potential value inflection. With ACXP a micro-cap biotech, the rally may also have been amplified by momentum trading and repositioning ahead of the company’s upcoming business update on its March 13, 2026 call.

Details:

The company disclosed a new initiative to study ibezapolstat in rCDI, starting with an open-label pilot trial designed to enroll up to 20 multiply-recurrent patients (at least two recurrences within the past 12 months).

Management said trial start-up activities are expected to begin later in March 2026, with first-patient enrollment anticipated in the fourth quarter of 2026.

The company plans to use the pilot data to help shape an active-controlled Phase 3 registration trial in rCDI and has signaled an intent to pursue FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) following a successful pivotal study.

In the same filing, executives and directors agreed to 10% voluntary cash compensation reductions (effective April 1, 2026), a cost-alignment step that may have helped sentiment around funding runway.

Sources:

U.S. Securities and Exchange Commission, Acurx Pharmaceuticals

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ACXP Hedge Fund Activity

We have seen 10 institutional investors add shares of $ACXP stock to their portfolio, and 23 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ARMISTICE CAPITAL, LLC removed 53,927 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $231,346
MILLENNIUM MANAGEMENT LLC added 41,427 shares (+inf%) to their portfolio in Q4 2025, for an estimated $103,153
VANGUARD GROUP INC added 23,280 shares (+inf%) to their portfolio in Q4 2025, for an estimated $57,967
NORTHERN TRUST CORP added 16,914 shares (+inf%) to their portfolio in Q4 2025, for an estimated $42,115
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 16,815 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $41,869
GEODE CAPITAL MANAGEMENT, LLC added 12,417 shares (+inf%) to their portfolio in Q4 2025, for an estimated $30,918
JANE STREET GROUP, LLC added 10,743 shares (+inf%) to their portfolio in Q4 2025, for an estimated $26,750

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ACXP Analyst Ratings

Wall Street analysts have issued reports on $ACXP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 09/30/2025

To track analyst ratings and price targets for $ACXP, check out Quiver Quantitative's $ACXP forecast page.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.